Associated Papers
Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report.
Blumendeller C et al.
Journal for Immunotherapy of Cancer, 2021
33431630 (PubMed )
Supplement: jitc-2020-001406supp001.pdf
Select a paper to view details